Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs

American Journal of Veterinary Research

Volumn 71, Issue 3, 2010, Pages 349-358

  Blois, Shauna L ^a   Allen, Dana G ^a   Wood, R Darren ^a   Conlon, Peter D ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CARPROFEN; DERACOXIB; FIBRINOGEN; MELOXICAM; PROSTAGLANDIN; THROMBOXANE B2;

ANALYZER; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; CARBAZOLES; DOGS; FEMALE; MALE; OVARIECTOMY; PLATELET AGGREGATION; PROSTAGLANDINS; SULFONAMIDES; THIAZINES; THIAZOLES;

ANIMALIA; CANIS FAMILIARIS;

EID: 77950999865     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.3.349     Document Type: Article

References (57)

1. Livingston A. Mechanism of action of nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract 2000;30:773-781.
2. Jones RD, Baynes RE, Nimitz CT. Nonsteroidal anti-inflammatory drug toxicosis in dogs and cats: 240 cases (1989-1990). J Am Vet Med Assoc 1992;201:475-477.
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
4. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000;217:721-729.
5. Tomlinson J, Blikslager A. Role of nonsteroidal anti-inflammatory drugs in gastrointestinal tract injury and repair. J Am Vet Med Assoc 2003;222:946-951. (Pubitemid 36363242)
6. FitzGerald G. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890. (Pubitemid 37407794)
7. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998;59:1441-1446.
8. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002;63:91-94.
9. Wilson JE, Chandrasekharan NV, Westover KD, et al. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res 2004;65:810-818.
10. Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:812-817.
11. McCann ME, Andersen DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004;65:503-512.
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
13. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
14. Cheng Y, Austin S, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-541. (Pubitemid 34408674)
15. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995;35:209-219.
16. Dusting GJ, Moncada S, Vane JR. Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins 1977;13:3-15. (Pubitemid 8030252)
17. Krotz F, Schiele TM, Klauss V, et al. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005;42:312-324. (Pubitemid 41160232)
18. Rackear D, Feldman B, Farver T, et al. The effect of three different dosages of acetylsalicylic acid on canine platelet aggregation. J Am Anim Hosp Assoc 1988;12:201-238.
19. Brainard BM, Meredith CP, Callan MB, et al. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res 2007;68:251-257.
20. Nielsen LA, Zois NE, Pedersen HD, et al. Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007;36:267-273.
21. Luna SP, Basilio AC, Steagall PV, et al. Evaluation of adverse ef fects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 2007;68:258-264.
22. Hickford FH, Barr SC, Erb HN. Effect of carprofen on hemostatic variables in dogs. Am J Vet Res 2001;62:1642-1646.
23. Gaal T, Halmay D, Kocsis R, et al. Evaluation of the effect of ketoprofen and carprofen on platelet function in dogs studied by PFA-100 point-of-care analyser. Acta Vet Hung 2007;55:287-294.
24. Bergmann HM, Nolte IJ, Kramer S. Effects of preoperative administration of carprofen on renal function and hemostasis in dogs undergoing surgery for fracture repair. Am J Vet Res 2005;66:1356-1363. (Pubitemid 41613989)
25. Kay-Mugford P, Benn SJ, LaMarre J, et al. In vitro effects of non-steroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res 2000;61:802-810.
26. Fresno L, Moll J, Penalba B, et al. Effects of preoperative administration of meloxicam on whole blood platelet aggregation, buccal mucosal bleeding time, and haematological indices in dogs undergoing elective ovariohysterectomy. Vet J 2005;170:138-140. (Pubitemid 40916345)
27. Deneuche AJ, Dufayet C, Goby L, et al. Analgesic comparison of meloxicam or ketoprofen for orthopedic surgery in dogs. Vet Surg 2004;33:650-660. (Pubitemid 41754977)
28. Allen D, Dowling P, Smith D, et al. Drugs in small animals. In: Allen D, Dowling P, Smith D, et al, eds. Handbook of veterinary drugs. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2005;5-54.
29. Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62:652-658. (Pubitemid 33606115)
30. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43-52. (Pubitemid 37555034)
31. Yilmaz Z, Ilcol YO, Torun S, et al. Intravenous administration of choline or cdp-choline improves platelet count and platelet closure times in endotoxin-treated dogs. Shock 2006;25:73-79. (Pubitemid 43755990)
32. Gemmons RM, Meyers KM. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984;45:137-144.
33. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975;72:2994-2998.
34. Rosenkranz B, Fischer C, Reimann I, et al. Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man. Biochim Biophys Acta 1980;619:207-213. (Pubitemid 10022690)
35. Jones CJ, Streppa HK, Harmon BG, et al. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res 2002;63:1527-1531.
36. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
37. Gentry PA. Comparative aspects of blood coagulation. Vet J 2004;168:238-251.
38. Grauer GF, Rose BJ, Toolan L, et al. Effects of low-dose aspirin and specific thromboxane synthetase inhibition on whole blood platelet aggregation and adenosine triphosphate secretion in healthy dogs. Am J Vet Res 1992;53:1631-1635.
39. Boudreaux MK, Dillon AR, Ravis WR, et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res 1991;52:1992-1999.
40. Jackson ML, Searcy GP, Olexson DW. The effect of oral phenylbutazone on whole blood platelet aggregation in the dog. Can J Comp Med 1985;49:271-277. (Pubitemid 15017206)
41. McAdam B, Catella-Lawson F, Mardini I, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277. (Pubitemid 29036089)
42. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979;63:532-535.
43. Hwang DH. Species variation in platelet aggregation. In: Longenecker GL, ed. Platelets: physiology and pharmacology. Orlando, Fla: Academic Press Inc, 1985;289.
44. Kazakos GM, Papazoglou LG, Rallis T, et al. Effects of meloxicam on the haemostatic profile of dogs undergoing orthopaedic surgery. Vet Rec 2005;157:444-446. (Pubitemid 41582262)
45. Mathews KA, Pettifer G, Foster R, et al. Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. Am J Vet Res 2001;62:882-888. (Pubitemid 32505974)
46. Heilmann E, Friese P, Anderson S, et al. Biotinylated platelets: a new approach to the measurement of platelet life span. Br J Haematol 1993;85:729-735. (Pubitemid 24003588)
47. Allen D, Dowling P, Smith D, et al. Description of drugs for small animals. In: Allen D, Dowling P, Smith D, et al, eds. Handbook of veterinary drugs. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2005;97-401.
48. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49. (Pubitemid 35284424)
49. Homoncik M, Jilma B, Hergovich N, et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321. (Pubitemid 30093238)
50. Tarnow I, Kristensen AT, Texel H, et al. Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2003;17:680-686. (Pubitemid 37229848)
51. Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. J Clin Invest 1993;92:2469-2479.
52. Mortensen J, Poulsen TS, Grove EL, et al. Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest 2008;68:786-792.
53. Kurata M, Ishizuka N, Matsuzawa M, et al. A comparative study of whole-blood platelet aggregation in laboratory animals: its species differences and comparison with turbidimetric method. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995;112:359-365. (Pubitemid 26038874)
54. So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003;1:2510-2515.
55. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 2007;5:2376-2385. (Pubitemid 350154346)
56. FitzGerald G, Patrone C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442.
57. Weber AA, Heim HK, Schumacher M, et al. Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers. Platelets 2007;18:379-385. (Pubitemid 47123837)